Neuroendocrine Tumor Patient Experience and Disease Burden: Results From the First Global NET Patient Survey—A Collaboration Between the International Neuroendocrine Cancer Alliance (INCA) and Novartis Pharmaceuticals

Philippe Ruszlewski, James C. Yao, Teodora Kolarova, Grace Geldstein, Maia Sisson, John Leyden

University of Paris VII and Basset Hospital, Paris, France; The University of Texas MD Anderson Cancer Center, Houston, TX, USA; J.P. & Friends, Sofia, Bulgaria; The Carcinoid Cancer Foundation, Inc., White Plains, NY, USA; NET Patient Foundation and Food for Life Foundation, United Kingdom; The Unicancer Foundation, Malmö, Sweden; Australia, New Zealand, Australia

Presented at the European Neuroendocrine Tumor Society (ENETS) 12th Annual Conference, 11-13 March 2015, Barcelona, Spain

Novartis Pharmaceuticals Corporation provided funding for the survey. © 2015 Novartis Pharmaceuticals Corporation, used under license by INCA and its member organizations.